Universitätsklinikum Köln

Running trials

• Recruiting

  Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study

  NCT07264426· Source

• Active, not recruiting

  Study of GS-0151 in Participants With Rheumatoid Arthritis

  NCT06902519· Phase 1· Source

• Recruiting

  A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

  NCT06925542· Phase 1· Source

• Active, not recruiting

  Xeltis Hemodialysis Access Graft: aXess Pivotal Study

  NCT05473299· Source

• Recruiting

  The "Global Paradise System" Registry

  NCT05027685· Source

• Active, not recruiting

  A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

  NCT04106219· Phase 1· Source

• Recruiting

  A Study to Assess Effectiveness and Efficiency of VNS Therapy in Patients With Difficult to Treat Depression.

  NCT03320304· Source

• Recruiting

  GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial

  NCT02872987· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute lymphoblastic leukaemia1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Depression1 recruiting
• High blood pressure1 recruiting
• Lupus (SLE)1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID

  NCT05911009· Phase 2· Source

• Completed

  Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

  NCT05804032· Phase 3· Source

• Terminated

  Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

  NCT04778397· Phase 3· Source

• Completed

  A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT04777201· Phase 3· Source

• Completed

  Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors

  NCT04696055· Phase 2· Source

• Completed

  Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment

  NCT04511455· Phase 2· Source

• Completed

  REcanalization of Distal Cerebral Vessels in Acute Stroke Using ApeRio®

  NCT04479020· Source

• Terminated

  Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients

  NCT04261777· Phase 3· Source

• Completed

  Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma

  NCT03473756· Phase 1· Source

• Completed

  A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

  NCT02975934· Phase 3· Source

• Completed

  Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

  NCT02902029· Phase 2· Source

• Completed

  Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis

  NCT02923206· Source

• Completed

  A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

  NCT02500407· Phase 1/2· Source

• Completed

  R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL

  NCT01865110· Phase 3· Source